FDA approves Asahi Kasei’s Hovilpri for refractory HSV

Asahi Kasei Therapeutics is the global specialty pharmaceutical unit of Tokyo’s Asahi Kasei. Credit: Asahi Kasei Therapeutics/Business Wire.



  • FDA Asahi Kasei